Chapter 22 Pharmacogenomics for forensic toxicology in enabling personalized medicine
作者： Steven H.Y. Wong
DOI: 10.1016/S1567-7192(06)06022-0
关键词:
摘要: Publisher Summary This chapter discusses pharmacogenomics for forensic toxicology in enabling personalized medicine. With the completion of human genome project, one most tangible benefits is emerging practice as a part genomic and While pharmacogenetics are currently used interchangeably, readily defined study genetic effect—for example, single nucleotide polymorphism (SNP)—on an individual's ability to metabolize drug or compound, whereas concerned with whole effect on metabolism efficacy. Pharmacogenomic biomarker, combination well-accepted biomarkers such therapeutic monitoring other functional testing, proteomic possibly molecular imaging, enables The identifies right patient, diagnosis/treatment, matching drug, dose, at time, thus achieving clinical efficacy no minimized toxicity.
elsevier.com
sci-hub.se 参考文章(37)
Steven H. Wong, Michael A. Wagner, Jeffrey M. Jentzen, Chuck Schur, Jeanette Bjerke, Susan B. Gock, Chung-Che Chang, Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? Journal of Forensic Sciences. ,vol. 48, pp. 1406- 1415 ,(2003) , 10.1520/JFS2002392
Jeffrey M Drazen, Francic S. Collins, Alan E. Guttmacher, Genomic medicine : articles from the New England Journal of Medicine The Johns Hopkins University Press. ,(2004)
Tietz's applied laboratory medicine Wiley-Interscience. ,(2007) , 10.1002/0470086084
MW Linder, R Valdes, Fundamentals and applications of pharmacogenetics for the clinical laboratory. Annals of Clinical and Laboratory Science. ,vol. 29, pp. 140- 149 ,(1999)
Kenneth Offit, Michal Sagi, Karen Hurley, Preimplantation Genetic Diagnosis for Cancer Syndromes JAMA. ,vol. 296, pp. 2727- 2730 ,(2006) , 10.1001/JAMA.296.22.2727
William L Trepicchio, Grant A Williams, David Essayan, Sue T Hall, Lea C Harty, Peter M Shaw, Brian B Spear, Sue Jane Wang, Mark L Watson, Pharmacogenomic data submissions to the FDA: clinical case studies Pharmacogenomics. ,vol. 5, pp. 519- 524 ,(2004) , 10.1517/14622416.5.5.519
D Gurwitz, J E Lunshof, G Dedoussis, C S Flordellis, U Fuhr, J Kirchheiner, J Licinio, A Llerena, V G Manolopoulos, L J Sheffield, G Siest, F Torricelli, V Vasiliou, S Wong, Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics Journal. ,vol. 5, pp. 221- 225 ,(2005) , 10.1038/SJ.TPJ.6500312
Leif Bertilsson, Ya-Qing Lou, Yun-Long Du, Yin Liu, Tang-Yun Kuang, Xia-Mau Liao, Ke-Yi Wang, Jesús Reviriego, Lennart Iselius, Folke Sjöqvist, Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin Clinical Pharmacology and Therapeutics. ,vol. 51, pp. 388- 397 ,(1992) , 10.1038/CLPT.1992.38
Gualberto Ruaño, Jerry M Collins, Andrew J Dorner, Sue-Jane Wang, Roberto Guerciolini, Shiew-Mei Huang, Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics. ,vol. 5, pp. 513- 517 ,(2004) , 10.1517/14622416.5.5.513
Eiji Araki, Masayuki Ishikawa, Masaaki Iigo, Tsutomu Koide, Masayuki Itabashi, Akio Hoshi, Relationship between Development of Diarrhea and the Concentration of SN-38, an Active Metabolite of CPT-11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT-11 Japanese Journal of Cancer Research. ,vol. 84, pp. 697- 702 ,(1993) , 10.1111/J.1349-7006.1993.TB02031.X